PT3468965T - Compostos de 1-tetra-hidropiranilcarbonil-2,3-di-hidro-1h-indole para tratamento de cancro - Google Patents
Compostos de 1-tetra-hidropiranilcarbonil-2,3-di-hidro-1h-indole para tratamento de cancroInfo
- Publication number
- PT3468965T PT3468965T PT177289907T PT17728990T PT3468965T PT 3468965 T PT3468965 T PT 3468965T PT 177289907 T PT177289907 T PT 177289907T PT 17728990 T PT17728990 T PT 17728990T PT 3468965 T PT3468965 T PT 3468965T
- Authority
- PT
- Portugal
- Prior art keywords
- tetrahydropyranylcarbonyl
- dihydro
- treating cancer
- indole compounds
- indole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348457P | 2016-06-10 | 2016-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3468965T true PT3468965T (pt) | 2020-07-16 |
Family
ID=59031409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177289907T PT3468965T (pt) | 2016-06-10 | 2017-05-31 | Compostos de 1-tetra-hidropiranilcarbonil-2,3-di-hidro-1h-indole para tratamento de cancro |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US9872853B2 (pt) |
| EP (1) | EP3468965B1 (pt) |
| JP (1) | JP6632746B2 (pt) |
| KR (1) | KR102241258B1 (pt) |
| CN (1) | CN109641881B (pt) |
| AR (1) | AR108586A1 (pt) |
| AU (1) | AU2017277833B2 (pt) |
| BR (1) | BR112018072872A2 (pt) |
| CA (1) | CA3027035C (pt) |
| CL (1) | CL2018003543A1 (pt) |
| CO (1) | CO2018013251A2 (pt) |
| CR (1) | CR20180579A (pt) |
| CY (1) | CY1123660T1 (pt) |
| DK (1) | DK3468965T3 (pt) |
| DO (1) | DOP2018000278A (pt) |
| EA (1) | EA037419B1 (pt) |
| EC (1) | ECSP19001734A (pt) |
| ES (1) | ES2797981T3 (pt) |
| HR (1) | HRP20200769T1 (pt) |
| HU (1) | HUE050155T2 (pt) |
| IL (1) | IL263497B (pt) |
| JO (1) | JOP20170131B1 (pt) |
| LT (1) | LT3468965T (pt) |
| MA (1) | MA45224B1 (pt) |
| MD (1) | MD3468965T2 (pt) |
| ME (1) | ME03744B (pt) |
| MX (1) | MX2018015275A (pt) |
| MY (1) | MY197462A (pt) |
| NZ (1) | NZ748500A (pt) |
| PE (1) | PE20190378A1 (pt) |
| PH (1) | PH12018502572A1 (pt) |
| PL (1) | PL3468965T3 (pt) |
| PT (1) | PT3468965T (pt) |
| RS (1) | RS60322B1 (pt) |
| SG (1) | SG11201809625RA (pt) |
| SI (1) | SI3468965T1 (pt) |
| TW (1) | TWI671294B (pt) |
| UA (1) | UA122526C2 (pt) |
| WO (1) | WO2017213919A1 (pt) |
| ZA (1) | ZA201807688B (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| KR102398439B1 (ko) | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| TWI811236B (zh) | 2017-08-28 | 2023-08-11 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| WO2019089412A1 (en) * | 2017-11-01 | 2019-05-09 | Merck Sharp & Dohme Corp. | Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| WO2019126257A1 (en) * | 2017-12-21 | 2019-06-27 | Merck Patent Gmbh | Combination of an anti-pd-l1 antibody and ido1 inhibitor for the treatment of cancer |
| WO2019143902A2 (en) | 2018-01-22 | 2019-07-25 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2020036837A1 (en) * | 2018-08-17 | 2020-02-20 | Merck Sharp & Dohme Corp. | Novel substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors |
| UY38383A (es) | 2018-09-21 | 2020-04-30 | Enanta Pharm Inc | Heterociclos funcionalizados como agentes antivirales |
| WO2020096871A1 (en) | 2018-11-06 | 2020-05-14 | Merck Sharp & Dohme Corp. | Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors |
| KR20210093951A (ko) | 2018-11-21 | 2021-07-28 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스제로서의 작용화된 헤테로사이클 |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CN114105961B (zh) * | 2021-12-10 | 2023-09-12 | 海南梵圣生物科技有限公司 | 一种ido1抑制剂(ly-3381916)制备方法 |
| CN114213310B (zh) * | 2021-12-31 | 2024-02-23 | 中国药科大学 | 吲哚啉化合物及其衍生物、制备方法、药物组合物和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1787982B1 (en) * | 2003-04-11 | 2010-05-12 | High Point Pharmaceuticals, LLC | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds |
| PL2559690T3 (pl) * | 2005-05-10 | 2016-09-30 | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania | |
| US7622495B2 (en) * | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| JP2011511800A (ja) * | 2008-02-07 | 2011-04-14 | アボット・ラボラトリーズ | 正のアロステリックな修飾物質としてのアミド誘導体およびこれらの使用方法 |
| CA2743975C (en) * | 2008-07-08 | 2018-09-11 | Incyte Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| NO2694640T3 (pt) * | 2011-04-15 | 2018-03-17 | ||
| CN105324362B (zh) * | 2013-03-15 | 2017-05-24 | 百时美施贵宝公司 | Ido抑制剂 |
| KR20160140892A (ko) * | 2014-04-04 | 2016-12-07 | 아이오메트 파마 엘티디 | 의약에 사용하기 위한 인돌 유도체 |
| UY36391A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| EP3405587A4 (en) * | 2015-12-23 | 2019-10-30 | Moonshot Pharma LLC | METHOD FOR TRIGGERING AN IMMUNE REACTION THROUGH READ THROUGH PROMOTION OF A PREVIOUS TERMINATION CODON |
-
2017
- 2017-05-24 AR ARP170101413A patent/AR108586A1/es unknown
- 2017-05-24 JO JOP/2017/0131A patent/JOP20170131B1/ar active
- 2017-05-25 TW TW106117300A patent/TWI671294B/zh active
- 2017-05-31 SG SG11201809625RA patent/SG11201809625RA/en unknown
- 2017-05-31 MY MYPI2018002369A patent/MY197462A/en unknown
- 2017-05-31 MA MA45224A patent/MA45224B1/fr unknown
- 2017-05-31 DK DK17728990.7T patent/DK3468965T3/da active
- 2017-05-31 ME MEP-2020-98A patent/ME03744B/me unknown
- 2017-05-31 LT LTEP17728990.7T patent/LT3468965T/lt unknown
- 2017-05-31 PT PT177289907T patent/PT3468965T/pt unknown
- 2017-05-31 AU AU2017277833A patent/AU2017277833B2/en not_active Ceased
- 2017-05-31 US US15/609,115 patent/US9872853B2/en active Active
- 2017-05-31 JP JP2018563823A patent/JP6632746B2/ja active Active
- 2017-05-31 PE PE2018003199A patent/PE20190378A1/es unknown
- 2017-05-31 MD MDE20190462T patent/MD3468965T2/ro unknown
- 2017-05-31 ES ES17728990T patent/ES2797981T3/es active Active
- 2017-05-31 EP EP17728990.7A patent/EP3468965B1/en active Active
- 2017-05-31 CA CA3027035A patent/CA3027035C/en active Active
- 2017-05-31 SI SI201730252T patent/SI3468965T1/sl unknown
- 2017-05-31 CN CN201780035976.4A patent/CN109641881B/zh not_active Expired - Fee Related
- 2017-05-31 BR BR112018072872-1A patent/BR112018072872A2/pt not_active Application Discontinuation
- 2017-05-31 NZ NZ748500A patent/NZ748500A/en not_active IP Right Cessation
- 2017-05-31 RS RS20200623A patent/RS60322B1/sr unknown
- 2017-05-31 CR CR20180579A patent/CR20180579A/es unknown
- 2017-05-31 HU HUE17728990A patent/HUE050155T2/hu unknown
- 2017-05-31 UA UAA201811735A patent/UA122526C2/uk unknown
- 2017-05-31 EA EA201892479A patent/EA037419B1/ru unknown
- 2017-05-31 WO PCT/US2017/035097 patent/WO2017213919A1/en unknown
- 2017-05-31 US US16/307,612 patent/US10759786B2/en active Active
- 2017-05-31 MX MX2018015275A patent/MX2018015275A/es unknown
- 2017-05-31 KR KR1020187035215A patent/KR102241258B1/ko active IP Right Grant
- 2017-05-31 PL PL17728990T patent/PL3468965T3/pl unknown
-
2018
- 2018-11-15 ZA ZA2018/07688A patent/ZA201807688B/en unknown
- 2018-12-04 IL IL263497A patent/IL263497B/en active IP Right Grant
- 2018-12-06 CO CONC2018/0013251A patent/CO2018013251A2/es unknown
- 2018-12-06 PH PH12018502572A patent/PH12018502572A1/en unknown
- 2018-12-10 DO DO2018000278A patent/DOP2018000278A/es unknown
- 2018-12-10 CL CL2018003543A patent/CL2018003543A1/es unknown
-
2019
- 2019-01-09 EC ECSENADI20191734A patent/ECSP19001734A/es unknown
-
2020
- 2020-05-12 HR HRP20200769TT patent/HRP20200769T1/hr unknown
- 2020-06-05 CY CY20201100508T patent/CY1123660T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263497B (en) | 1-tetrahydropyranylcarbonyl-3,2-dihydro-h1-indole compounds for cancer treatment | |
| HK1251407A1 (zh) | 治療癌症的方法 | |
| ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| IL260444B (en) | Anti-her2 combinations for cancer treatment | |
| RS63561B1 (sr) | Kompozicija za lečenje raka | |
| IL260442B (en) | Combinations of anti-cd20 for cancer treatment | |
| IL249229A0 (en) | Compounds for the treatment of brain cancer | |
| HK1254258A1 (zh) | 使用阿吡莫德治療癌症的方法 | |
| EP3405203A4 (en) | METHODS OF TREATING CANCER | |
| EP3389634A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| EP3440112A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| HK1250944A1 (zh) | 用於治療癌症的方法 | |
| GB201709405D0 (en) | Compounds for treating ovarian cancer | |
| EP3389652A4 (en) | METHODS OF TREATING CANCER | |
| HK1250942A1 (zh) | 用於治療癌症的方法 | |
| HK1250943A1 (zh) | 用於治療癌症的方法 | |
| EP3296294A4 (en) | Compound for treating or preventing breast cancer | |
| HK1259615A1 (zh) | 谷氨酸-高z元素化合物治療癌症 | |
| PT3580211T (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro | |
| AU2014904697A0 (en) | Compounds for treating cancer |